Prescribing information

 

This animated video highlights the key efficacy and safety data from the COMBI-AD Phase III clinical trial assessing TAFINLAR (dabrafenib) and MEKINIST (trametinib) for the adjuvant treatment of adult patients with BRAF V600-positive Stage III melanoma, following complete resection1.

Further data from the COMBI-AD trial can be viewed here.

References

  1. Hauschild A, et al. J Clin Oncol 2020; 38(suppl) [abstract 10001].
  2. The Cancer Genome Atlas Network. Cell 2015; 161(7):1681-1696.
  3. Hayward NK, et al. Nature 2017; 545(7653):175-180.
  4. Rabbie R, et al. J Pathol 2019; 247(5):539-551.
  5. Ives NJ, et al. Eur J Cancer 2017; 82:171-183.
  6. Michielin O, et al. Ann Oncol 2019; 30(12):1884-1901.
  7. Hauschild A, et al. J Clin Oncol 2018; 36(35):3441-3449.
  8. Long GV, et al. N Engl J Med 2017; 377(19):1813-1823.
  9. Eggermont AM, et al. J Clin Oncol 2020; 38(suppl) [abstract 10000].
  10. Schadendorf D, et al. Lancet Oncol 2019; 20(5):701-710.
  11. Atkinson V, et al. Presented at ESMO 2018; 19-23 October, Munich, Germany.
  12. Long GV, et al. Presented at SMR 2017; 18-21 October, Brisbane, Australia.
  13. Novartis Pharmaceutical Corp. Data on file 2018.
  14. TAFINLAR (dabrafenib) Summary of Product Characteristics.
  15. MEKINIST (trametinib) Summary of Product Characteristics.
  16. OPDIVO (nivolumab) Summary of Product Characteristics.
  17. KEYTRUDA (pembrolizumab) Summary of Product Characteristics.
  18. Eek D, et al. Patient Prefer Adherence 2016; 10:1609-1621.
UK | December 2020 | 100924
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]